PlainPharmaWatch

CMS Open Payments · Program Year 2024

Corcept Therapeutics

Corcept Therapeutics reported $4,181,168.42 across General Payments, Research, and Ownership to 34,550 physicians and teaching hospitals across 34,877 transactions.

$4.2M
All-tracks total
34,877
Transactions
34,550
Recipients
+$1.7M
General Payments vs PY2023

Corcept Therapeutics reported $4,181,168.42 across all CMS Open Payments tracks (General + Research + Ownership) to 34,550 physicians and teaching hospitals in Program Year 2024 - ranking #300 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $3,892,659.80, averaging $121.02 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer corcept-therapeutics Corcept Therapeutics

$4.2M · #300/1,925 · 0.0% industry · PY2024

  • TOT $4.2M
  • RANK #300
  • SHARE 0.0%
  • TXN 34,877
  • RCP 34,550
  • CAT 8
  • GEN $3.9M
  • ΔGEN +$1.7M
  • TOP1 3.0%
  • PY 2024

Nearest volume peer: Johnson & Johnson Surgical Vision, Inc. ($4.2M)

Sonex Health, Inc.$4.2MIpsen Bioscience Inc.$4.2MCorcept Therapeutics (this)$4.2MJohnson & Johnson Surgical V…$4.2MResponsive Arthroscopy Inc$4.1M
All-tracks payment totals near Corcept Therapeutics (CMS Open Payments PY2024)

Corcept Therapeutics sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Corcept Therapeutics's CMS-reported General Payments increased by $1.7M (+74.5%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: CORCEPT THERAPEUTICSPY2023: CORCEPT THERAPEUTICSPY2024: Corcept Therapeutics. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$2.2MPY2024$3.9M
PY2023
$2,231,107.00
PY2024
$3,892,659.80

What the Data Shows for Corcept Therapeutics

$4,181,168.42: that is what Corcept Therapeutics reported in payments to 34,550 physicians and teaching hospitals during Program Year 2024, spread across 34,877 transactions ($119.88 per transaction, $121.02 per recipient). The company sits at rank #300 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

"Compensation for Services Other Than Consulting" leads the 8-category general-payment breakdown below at $1.9M (48.4% of General Payments, 784 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Corcept Therapeutics made 8 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $1.9M, 48.4% of General Payments.

Corcept Therapeutics reports 8 general-payment categories - the top three are Compensation for Services Other Than Consulting (48.4%), Food and Beverage (22.4%), and Travel and Lodging (11.6%). The remaining 5 categories make up 17.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

Category breadth matters here: Corcept Therapeutics files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.

How Corcept Therapeutics divides its payments

Ranked by total dollars reported per category

1. Compensation for Services…$1.9M2. Food and Beverage$873.1K3. Travel and Lodging$451.7K4. Honoraria$387.6K5. Consulting Fee$229.4K6. Space Rental or Facility …$44.0K7. Grant$15.6K8. Education$7.7K
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $1.9M 784
Food and Beverage $873.1K 32,077
Travel and Lodging $451.7K 1,011
Honoraria $387.6K 106
Consulting Fee $229.4K 93
Space Rental or Facility Fees $44.0K 15
Grant $15.6K 3
Education $7.7K 461

Recipient Concentration in General Payments

The five largest recipient relationships account for $549,145.18 (14.1%) of $3,892,659.80 in this company's General Payments records across 11,467 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Corcept Therapeutics

The five named recipients with the highest reported General Payments from this company

Hanford Yau$117.5KLance Sloan$111.2KAlison Lynn Gracom$107.4KChristopher Lucci$107.0KSaleemah Fahmi$106.1K
  1. 1

    Hanford Yau

    $117,521.35 across 137 reported transactions

  2. 2

    Lance Sloan

    $111,218.77 across 93 reported transactions

  3. 3

    Alison Lynn Gracom

    $107,362.34 across 149 reported transactions

  4. 4

    Christopher Lucci

    $106,988.69 across 99 reported transactions

  5. 5

    Saleemah Fahmi

    $106,054.03 across 126 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Corcept Therapeutics's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Corcept Therapeutics.

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Corcept Therapeutics.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Corcept Therapeutics's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.